Soleno Therapeutics, Inc. Common Stock (SLNO)
Soleno Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and neglected diseases. The company's primary focus has been on treatments for neurological and metabolic disorders, aiming to address unmet medical needs through innovative drug development.
Company News
Biotechnology company Cassava Sciences announced the appointment of Dawn C. Bir to its Board of Directors, bringing extensive biopharmaceutical executive experience to support the company's clinical development of simufilam for TSC-related epilepsy.
Soleno Therapeutics reported its first commercial quarter with VYKAT XR for Prader-Willi syndrome, delivering $32.7 million in revenue, exceeding analyst expectations. The company showed promising early demand with 646 patient start forms and is preparing for potential European market entry.
Soleno Therapeutics, a medical device company, has entered into an agreement with Jefferies LLC to potentially sell up to $150 million of its common stock. The new funding option aims to bolster the company's financial flexibility and support its ongoing operations and strategic initiatives.
U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc. (NASDAQ:AMZN) on Tuesday and Apple Inc. (NASDAQ:AAPL) on Thursday, a pivotal Federal Reserve Open Market Committee meeting on Wednesday, and the April’s ...
If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics, Inc. (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
